Lee Hong-Kee, McCarthy Cian P, Jaffe Allan S, Body Richard, Alotaibi Ahmed, Sandoval Yader, Januzzi James L
Department of Pathology and Laboratory Medicine, Endeavor Health, Evanston, IL, United States.
Department of Pathology, University of Chicago Pritzker School of Medicine, Chicago, IL, United States.
J Appl Lab Med. 2025 May 2;10(3):710-730. doi: 10.1093/jalm/jfae161.
Cardiac troponin is the gold-standard biomarker for the evaluation of patients with suspected acute myocardial infarction (MI). Improvements in assay technology have led to high-sensitivity cardiac troponin assays that, when incorporated into accelerated diagnostic pathways, may rapidly diagnose or exclude acute MI more efficiently than conventional troponin assays.
In this narrative review, we provide practical suggestions for implementing high-sensitivity cardiac troponin assays, review accelerated diagnostic pathways incorporating these assays, and review the impact of these assays on resource utilization and cost-effectiveness in relation to the evaluation of individuals with possible acute MI.
An increasing number of hospitals are transitioning to high-sensitivity cardiac troponin assays. This narrative review provides an overview of the potential benefits of this transition.
心肌肌钙蛋白是评估疑似急性心肌梗死(MI)患者的金标准生物标志物。检测技术的改进催生了高灵敏度心肌肌钙蛋白检测方法,将其纳入加速诊断流程后,可能比传统肌钙蛋白检测方法更高效地快速诊断或排除急性心肌梗死。
在本叙述性综述中,我们为实施高灵敏度心肌肌钙蛋白检测提供实用建议,回顾纳入这些检测方法的加速诊断流程,并探讨这些检测方法在评估可能患有急性心肌梗死的个体时对资源利用和成本效益的影响。
越来越多的医院正在转向高灵敏度心肌肌钙蛋白检测。本叙述性综述概述了这一转变的潜在益处。